埃里布林与达卡巴辛在先前接受过治疗的晚期脂肪瘤或乳腺肌肉瘤的患者中:一个随机的,开放的,多中心的第3期试验
Patrick Schöffski1, Sant Chawla2, Robert G Maki3
1Department of General Medical Oncology, University Hospitals Leuven, Leuven Cancer Institute, Leuven, Belgium.
Lancet (London, England)
|February 15, 2016
概括
与达卡巴相比,埃里布林显著改善了晚期软组织肉瘤患者的整体存活率. 这表明埃里布林是这种患者群体的可行的治疗选择.
科学领域:
- 癌症学
- 医学研究
- 临床试验
背景情况:
- 之前的第二阶段研究表明埃里布林在晚期或转移软组织肉瘤中的活性和耐受性.
- 这一第三阶段的研究旨在在更大的患者队列中验证埃里布林对达卡巴辛的疗效.
研究的目的:
- 在晚期或转移软组织肉瘤患者中比较埃里布林和达卡巴辛的整体存活期 (OS).
- 评估埃里布林作为晚期软组织肉瘤的潜在治疗选择.
主要方法:
- 一个随机的,开放的,涉及22个国家的110个地点的452名患者的3期试验.
- 患有晚期脂肪瘤或乳腺肌肉瘤的患者每21天服用埃里布林或达卡巴辛,直到疾病进展.
- 主要终点是治疗意向群体的整体存活率.
主要成果:
- 与达卡巴辛 (11.5 个月) 相比,埃里布林的总生存时间中位数显著改善 (HR 0.77, p=0. 0169).
- 治疗引起的不良反应在两组中都很常见 (99%的埃里布林,97%的达卡巴).
- 3级或更高的不良事件和死亡在埃里布林组中更为常见 (67%与56%相比).
结论:
- 与达卡巴相比,埃里布林显著改善了晚期软组织肉瘤患者的整体存活率.
- 埃里布林为晚期软组织肉瘤患者提供了潜在的新疗法.
更多相关视频
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
11.1K
06:11Laparoscopic Anatomical Resection of the Right Anterior Lobe Based on the Laennec Capsule Technique
Published on: May 2, 2025
710
相关概念视频
Treatment Resistant Cancers
3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Treatment Resistent Cancers
1.5K
1.5K
